Company intelligence / Profile preview

Guangzhou Aismab

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangzhou Aismab is an early-stage biotechnology company based in Guangzhou, China, specializing in the development of monoclonal antibody therapeutics. The company focuses on immuno-oncology, with a research pipeline targeting key immune checkpoints such as PD-1 and CTLA-4. Aismab leverages advanced antibody engineering to create next-generation biologics aimed at treating various solid tumors. While primarily in the pre-clinical phase, the company is actively building its portfolio to address unmet needs in cancer treatment through innovative immunotherapy solutions.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Guangzhou Aismab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Aismab.

Explore the full profile